Novartis is acquiring the monoclonal antibody Anthos, which was previously sold to Blackstone Life Sciences six years ago, in an up to $3.1 billion deal. The company has a history of revisiting some of its past investments, with the factor XI inhibitor being one such example that was sold in 2018. This move is seen as part of Novartis’ efforts to expand its portfolio and increase its presence in the market for anticoagulants.
Source: https://endpts.com/novartis-returns-for-its-anticoagulant-in-up-to-3-1b-buy-of-blackstones-anthos